Immunogen (Immunogen) Debt-to-Equity : 0.15 (As of Sep. 2023)

View and export this data going back to 1989. Start your Free Trial

What is Immunogen Debt-to-Equity?

Immunogen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $4.5 Mil. Immunogen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $79.9 Mil. Immunogen's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $561.6 Mil. Immunogen's debt to equity for the quarter that ended in Sep. 2023 was 0.15.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Immunogen's Debt-to-Equity or its related term are showing as below:

IMGN' s Debt-to-Equity Range Over the Past 10 Years
Min: -6.37 Med: 0.02 Max: 0.31
Current: 0.15

During the past 13 years, the highest Debt-to-Equity Ratio of Immunogen was 0.31. The lowest was -6.37. And the median was 0.02.

IMGN's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs IMGN: 0.15

Immunogen Debt-to-Equity Historical Data

The historical data trend for Immunogen's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunogen Debt-to-Equity Chart

Immunogen Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.19

-0.35

0.27

0.06

0.10

Immunogen Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial															0.09	0.10	0.12	0.17	0.15

Competitive Comparison of Immunogen's Debt-to-Equity

For the Biotechnology subindustry, Immunogen's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunogen's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunogen's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Immunogen's Debt-to-Equity falls into.

Immunogen Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Immunogen's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.096	+	11.148)	/	155.826
	=	0.10

Immunogen's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.458	+	79.872)	/	561.596
	=	0.15

Immunogen (NAS:IMGN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Immunogen Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Immunogen's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunogen (Immunogen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunogen Inc (NAS:IMGN) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

IMGN:Mexico IMU:Germany

Address

830 Winter Street, Waltham, MA, USA, 02451

Website

https://www.immunogen.com

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent.

Executives

Theresa Wingrove	officer: VP of Regulatory Affairs	IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Renee Lentini	officer: V.P.-Fin., Prin. Acctg. Off.	830 WINTER STREET, WALTHAM MA 02451
Stacy Ann Coen	officer: Chief Business Officer	11 RUSH POND RD, LAKEVILLE MA 02347
Kristine Peterson	director	AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
Lauren White	officer: SVP, CFO and PFO	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Mark J Enyedy	director, officer: Chief Executive Officer	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Isabel Kalofonos	officer: SVP & CHIEF COMMERCIAL OFFICER	C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Michael Vasconcelles	officer: EVP R&D & MEDICAL AFFAIRS	C/O UNUM THERAPEUTICS, 200 CAMBRIDGEPARK DR., STE. 3100, CAMBRIDGE MA 02140
Daniel Char	officer: SVP & CHIEF LEGAL OFFICER	C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Kristen Harrington-smith	officer: SVP & Chief Commercial Officer	C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Tracey L Mccain	director	C/O BLUEPRINTS MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Helen M. Thackray	director	C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
David G Foster	officer: V.P.-Fin., Prin. Acctg. Off.	C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Susan Altschuller	officer: SVP and CFO	45 TENNYSON ST., SOMERVILLE MA 02145
Craig Barrows	officer: Vice-President,General Counsel	C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451